Full Text
PRM160 - IMPACT OF POST-PROGRESSION OLARATUMAB (OLARA) MONOTHERAPY FOLLOWING DOXORUBICIN (DOX) MONOTHERAPY ON OVERALL SURVIVAL (OS).

Abstract

Authors

Y Dyachkova Y Lai PM Peterson SS Barker V Wacheck

Back to Volume 21, Supplemental S3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×